ArticleApplied biosafety : journal of the American Biological Safety Association2024
Five Things Not to Do When Discovering a Biosecurity Vulnerability.
Article in Applied biosafety : journal of the American Biological Safety Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Why implementation gaps could undermine synthetic nucleic acid oversight.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tools to screen orders submitted to companies synthesizing nucleic acids or machines that can synthesize them are vital to help ensure the building blocks for pathogens, toxins, or other biotechnology that could cause harm are kept in the right hands. Methods: The author has argued that it would be worrying if someone discovering a vulnerability in a nucleic acid synthesis tool was to (1) publicly release it without a "patch," (2) set an impossible timeframe to patch it before public release, (3) refuse to report it without a reward, (4) test it on a tool without the developer's/operator's consent, or (5) create a real biological hazard while exploring hypothetical biosecurity vulnerabilities. Conclusion: It will be a much harder challenge to develop a parallel set of behaviors desirable in such circumstances. This is a process that should start now. There will soon be a need for a safe, balanced, and reliable reporting infrastructure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.